DK2716304T3 - LIPOSOMHOLDIGT shRNA-MOLEKYLE, DER TARGETERER EN THYMIDYLATSYNTASE OG ANVENDELSE DERAF - Google Patents
LIPOSOMHOLDIGT shRNA-MOLEKYLE, DER TARGETERER EN THYMIDYLATSYNTASE OG ANVENDELSE DERAFInfo
- Publication number
- DK2716304T3 DK2716304T3 DK12790050.4T DK12790050T DK2716304T3 DK 2716304 T3 DK2716304 T3 DK 2716304T3 DK 12790050 T DK12790050 T DK 12790050T DK 2716304 T3 DK2716304 T3 DK 2716304T3
- Authority
- DK
- Denmark
- Prior art keywords
- lipid
- thymidylate synthase
- molecule targeting
- shrna molecule
- containing shrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011114946 | 2011-05-23 | ||
| PCT/JP2012/063082 WO2012161196A1 (ja) | 2011-05-23 | 2012-05-22 | チミジル酸合成酵素に対するｓｈＲＮＡ分子を含むリポソームおよびその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2716304T3 true DK2716304T3 (da) | 2017-11-27 |
Family
ID=47217272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12790050.4T DK2716304T3 (da) | 2011-05-23 | 2012-05-22 | LIPOSOMHOLDIGT shRNA-MOLEKYLE, DER TARGETERER EN THYMIDYLATSYNTASE OG ANVENDELSE DERAF |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120301537A1 (da) |
| EP (1) | EP2716304B1 (da) |
| JP (1) | JP5941460B2 (da) |
| CN (1) | CN103561775B (da) |
| DK (1) | DK2716304T3 (da) |
| ES (1) | ES2653923T3 (da) |
| HK (1) | HK1190325A1 (da) |
| HR (1) | HRP20171919T1 (da) |
| HU (1) | HUE037803T2 (da) |
| NO (1) | NO2716304T3 (da) |
| PL (1) | PL2716304T3 (da) |
| PT (1) | PT2716304T (da) |
| TW (1) | TWI442927B (da) |
| WO (1) | WO2012161196A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729180B1 (en) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| US20140255471A1 (en) | 2013-03-11 | 2014-09-11 | Wake Forest University Health Sciences | Method of treating brain tumors |
| CN105142613B (zh) * | 2013-04-30 | 2018-03-16 | 德尔塔菲制药股份有限公司 | 局部给药用脂质体及其用途 |
| JP6590802B2 (ja) * | 2013-11-06 | 2019-10-16 | ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体 |
| KR20160121584A (ko) * | 2014-02-26 | 2016-10-19 | 에트리스 게엠베하 | Rna의 위장 투여용 조성물 |
| KR101836877B1 (ko) * | 2014-10-30 | 2018-03-09 | 데루타-후라이 화마 가부시키가이샤 | 국소 투여용 리포플렉스의 신규 제조 방법 및 상기 리포플렉스를 사용하는 항 종양제 |
| JP7090034B2 (ja) | 2016-05-20 | 2022-06-23 | ザ ユニバーシティ オブ シカゴ | 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 |
| RU2765736C2 (ru) * | 2017-01-18 | 2022-02-02 | Темасек Лайф Сайенсиз Лаборатори Лимитед | Гиперстабилизированные липосомы, повышающие направленное таргетирование митотических клеток |
| WO2019012107A1 (en) * | 2017-07-13 | 2019-01-17 | Danmarks Tekniske Universitet | CATIONIC LIPOSOMES |
| EP3638367A4 (en) | 2017-08-02 | 2021-07-21 | The University of Chicago | NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE |
| JP6297737B1 (ja) | 2017-09-25 | 2018-03-20 | ジェイ−ネットワーク，インコーポレイテッド | 正に帯電した荷電ニオソームの調製方法及び荷電ニオソーム |
| CN114557964B (zh) * | 2022-03-17 | 2024-03-12 | 西安艾领克生物科技有限公司 | 一种可载rna的阳离子梭型柔性脂质体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202846B2 (en) * | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| JP4543188B2 (ja) * | 2004-03-10 | 2010-09-15 | 学校法人日本医科大学 | ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列 |
| CN101277704A (zh) * | 2005-04-12 | 2008-10-01 | 因特拉迪格姆公司 | 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法 |
| AU2007241370A1 (en) * | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
| WO2008035461A1 (fr) * | 2006-09-22 | 2008-03-27 | Taiho Pharmaceutical Co., Ltd. | Chimiothérapie adjuvante post-opératoire pour un cancer gastrique |
| DK2279254T3 (da) * | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | Hidtil ukendte lipidformuleringer til nukleinsyreindgivelse |
| WO2009149318A2 (en) * | 2008-06-05 | 2009-12-10 | Research Foundation Of State University Of New York | Mirnas as therapeutic targets in cancer |
| WO2010113844A1 (ja) * | 2009-03-31 | 2010-10-07 | 大鵬薬品工業株式会社 | チミジル酸合成酵素に対するＲＮＡｉ分子およびその用途 |
| JP5446781B2 (ja) | 2009-11-26 | 2014-03-19 | トヨタ自動車株式会社 | 左右独立駆動車両の駆動ユニット冷却装置 |
-
2011
- 2011-10-14 US US13/273,960 patent/US20120301537A1/en not_active Abandoned
-
2012
- 2012-05-22 EP EP12790050.4A patent/EP2716304B1/en active Active
- 2012-05-22 CN CN201280025004.4A patent/CN103561775B/zh active Active
- 2012-05-22 NO NO12790050A patent/NO2716304T3/no unknown
- 2012-05-22 PL PL12790050T patent/PL2716304T3/pl unknown
- 2012-05-22 ES ES12790050.4T patent/ES2653923T3/es active Active
- 2012-05-22 DK DK12790050.4T patent/DK2716304T3/da active
- 2012-05-22 JP JP2013516384A patent/JP5941460B2/ja active Active
- 2012-05-22 WO PCT/JP2012/063082 patent/WO2012161196A1/ja active Application Filing
- 2012-05-22 PT PT127900504T patent/PT2716304T/pt unknown
- 2012-05-22 HU HUE12790050A patent/HUE037803T2/hu unknown
- 2012-05-23 TW TW101118465A patent/TWI442927B/zh active
-
2014
- 2014-04-14 HK HK14103539.6A patent/HK1190325A1/zh unknown
-
2017
- 2017-12-11 HR HRP20171919TT patent/HRP20171919T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO2716304T3 (da) | 2018-03-10 |
| JP5941460B2 (ja) | 2016-06-29 |
| EP2716304B1 (en) | 2017-10-11 |
| HRP20171919T1 (hr) | 2018-02-09 |
| CN103561775A (zh) | 2014-02-05 |
| ES2653923T3 (es) | 2018-02-09 |
| PT2716304T (pt) | 2018-01-03 |
| HUE037803T2 (hu) | 2018-09-28 |
| HK1190325A1 (zh) | 2014-07-04 |
| EP2716304A4 (en) | 2014-10-29 |
| PL2716304T3 (pl) | 2018-03-30 |
| JPWO2012161196A1 (ja) | 2014-07-31 |
| CN103561775B (zh) | 2016-08-17 |
| TWI442927B (zh) | 2014-07-01 |
| EP2716304A1 (en) | 2014-04-09 |
| WO2012161196A1 (ja) | 2012-11-29 |
| US20120301537A1 (en) | 2012-11-29 |
| TW201300113A (zh) | 2013-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2716304T3 (da) | LIPOSOMHOLDIGT shRNA-MOLEKYLE, DER TARGETERER EN THYMIDYLATSYNTASE OG ANVENDELSE DERAF | |
| DK2726510T3 (da) | Dobbelt målretning | |
| SMT201600022B (it) | Pirrolobenzodiazepine e loro coniugati | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| CO6801645A2 (es) | Nuevos inmunoconjugados | |
| DK2920304T3 (da) | Oligonukleotidkonjugater | |
| DK2895484T3 (da) | Glucosylceramidsynthase-inhibitorer | |
| DK2761553T3 (da) | Betalingssystem | |
| DE112012002834A5 (de) | Achsträger | |
| CO6801749A2 (es) | Inhibidores de glucosilceramida sintasa | |
| BR112013032688A2 (pt) | artigo, e, cigarro | |
| ZA201401852B (en) | Aniline derivatives,their therapeutic application | |
| BR112014000021A2 (pt) | terapia direcionada para egfr | |
| EP2762139A4 (en) | ANTIMYCOTIC ACTIVE SUBSTANCE | |
| DE112012002319A5 (de) | Ballistikschutz | |
| FR2978994B1 (fr) | . | |
| ES1074812Y (es) | Cuadro para bicicleta | |
| DE112011102608T8 (de) | Cetanzahl-Bestimmungsvorrrichtung | |
| ITVA20110014A1 (it) | Idrossipropil guar | |
| FR2980843B1 (fr) | Projectile gyrostabilise | |
| FR2977524B1 (fr) | Piece assemblee par injection | |
| FR2974690B1 (fr) | Amplificateur | |
| FR2980994B1 (fr) | Prehenseur multi-plaquettes. | |
| ITCT20110009U1 (it) | Aroma santo | |
| IT1403676B1 (it) | Manufatti in ferrolega |